Passage Bio Inc expected to post a loss of 36 cents a share - Earnings Preview
Passage Bio Inc expected to post a loss of 40 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Coinbase Global, Spirit AeroSystems, Crown Castle
U.S. STOCKS ON THE MOVE-Toro, TRACON Pharma, Fulton Financial
U.S. STOCKS ON THE MOVE-Passage Bio, Discover Financial, Alphabet
Passage Bio rises on positive early-stage data for dementia treatment
Brief: Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial Of PBFT02 In FTD-GRN
Brief: Passage Bio Reports Q3 2023 Results And Provides Recent Business Highlights
Brief: Passage Bio Announces Interim Clinical Data From First Eight Patients With GM1 Gangliosidosis
Passage Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Passage Bio Q2 net income USD -23.856 million
Passage Bio Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Passage Bio Welcomes Dolan Sondhi, To Board Of Directors
Brief: Passage Bio Announced Organizational Redesign To Further Extend Its Cash Runway
Passage Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Passage Bio Reports Q1 2023 Financial Results And Provides Recent Business Highlights
U.S. RESEARCH ROUNDUP-Esperion Therapeutics, Office Properties Income Trust, Radius Global Infrastructure
Passage Bio Inc reports results for the quarter ended in December - Earnings Summary
Passage Bio Inc expected to post a loss of 52 cents a share - Earnings Preview